查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1600569

癌症/腫瘤分析市場：按技術、生物標記類型、癌症類型、應用分類 - 2025-2030 年全球預測

Cancer/Tumor Profiling Market by Technology (Immunoassays, In-Situ Hybridization, Mass Spectrometry), Biomarker Type (Genomic Biomarker, Protein Biomarker), Cancer Type, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年癌症/腫瘤分析市值為107.9億美元，預計到2024年將達到127.7億美元，複合年成長率為18.74%，到2030年將達到359.4億美元。

癌症/腫瘤分析在遺傳和分子層面上對癌細胞進行全面分析，以了解腫瘤異質性的複雜性並促進個人化治療策略。癌症分析的需求源於其在精準醫學中的重要作用，使腫瘤學家能夠根據個別生物標記物客製化治療方案，改善治療結果並最大限度地減少副作用。其應用涵蓋臨床診斷、藥物發現和腫瘤學研究，最終用戶為醫院、診斷實驗室、研究機構和製藥公司。市場成長的主要驅動力是癌症盛行率的增加、次世代定序（NGS）等分析技術的進步以及對個人化醫療的需求不斷成長。特別是，向高通量技術的轉變和具有成本效益的分析方法的開發為行業擴張提供了重大機會。此外，製藥公司和技術開發公司之間為增強標靶治療結成的聯盟可能會推動市場成長。然而，與先進定序平台相關的挑戰，例如高成本、資料隱私問題和缺乏熟練的專業人員，是主要障礙。此外，監管複雜性和報銷問題也構成了額外的障礙。潛在的創新領域在於開發整合生物資訊解決方案和人工智慧主導的分析，以增強資料解釋和預測建模。擴大液態切片和非侵入性分析方法的研究和開發工作可以為投資者和開發商開闢新的視野。市場正在動態發展，並且存在跨學科合作的趨勢，以利用全面的資料集來獲得可靠的臨床見解。為了利用新的商業機會，相關人員應專注於提高分析技術的可近性和可負擔性，建立策略聯盟，並投資人才發展計畫以縮小技能差距。將透過促進符合全球監管格局並滿足癌症治療的多樣化需求的創新來實現永續成長。

主要市場統計
基準年[2023] 107.9億美元
預測年份 [2024] 127.7億美元
預測年份 [2030] 359.4億美元
複合年成長率（%） 18.74%

市場動態：揭示快速發展的癌症/腫瘤分析市場的關鍵市場洞察

供需的動態交互作用正在改變癌症/腫瘤分析市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 在癌症患者治療中更多地採用生物標記
    • 政府機構和全球組織舉措開發癌症診斷的可用性
    • 癌症治療中個人化醫療越來越偏好
  • 市場限制因素
    • 癌症/腫瘤分析設備和服務的高資本投資
  • 市場機會
    • 次世代定序儀的出現和腫瘤分析的進展
    • 改進照護現場診斷技術以改善癌症檢測
  • 市場挑戰
    • 生物標記的發現和核准率較低

波特五力：駕馭癌症/腫瘤分析市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解癌症/腫瘤分析市場的外部影響

外部宏觀環境因素在塑造癌症/腫瘤分析市場的績效動態方面發揮關鍵作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解癌症/腫瘤分析市場的競爭格局

癌症/腫瘤分析市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣癌症/腫瘤分析市場供應商的績效評估

FPNV定位矩陣是評估癌症/腫瘤分析市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。四個象限清楚且準確地分類供應商，幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

本報告提供了涵蓋關鍵重點領域的全面市場分析：

1. 市場滲透率：對當前市場環境的詳細回顧，包括行業主要企業的大量資料。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 在癌症患者的治療中更多地採用生物標記
      • 各國政府和國際組織為開發癌症診斷方法所做的努力
      • 人們對癌症治療中的個人化醫療越來越感興趣
    • 抑制因素
      • 對癌症/腫瘤分析設備和服務的大量資本投資
    • 機會
      • 次世代定序的出現和腫瘤分析的進展
      • 改進照護現場診斷技術以改善癌症檢測
    • 任務
      • 生物標記的發現率和核准較低
  • 市場區隔分析
    • 技術：使用次世代定序(NGS) 尋找各種癌症的基因突變
    • 生物標記的類型：基因生物標記用於測量基因表現、基因功能和基因調控。
    • 癌症類型：廣泛推薦用於預測模型和臨床風險分層的前列腺癌癌症分析
    • 應用：在開發精準醫學中增加使用癌症/腫瘤分析來縮短癒合和恢復時間
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章癌症/腫瘤分析市場：依技術分類

  • 免疫檢測
  • 原位雜合技術
  • 質譜分析
  • 微陣列
  • 次世代定序
  • 聚合酵素鏈鎖反應

第 7 章按生物標記類型分類的癌症/腫瘤分析市場

  • 基因生物標記
  • 蛋白質生物標記

第 8 章按癌症類型分類的癌症/腫瘤分析市場

  • 乳癌
  • 大腸直腸癌
  • 肺癌
  • 黑色素瘤癌症
  • 攝護腺癌

第9章癌症/腫瘤分析市場：依應用分類

  • 生物標記發現
  • 臨床應用
  • 診斷
  • 個人化醫療
  • 預言
  • 調查
  • 篩檢
  • 治療和監測

第10章美洲癌症/腫瘤分析市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太癌症/腫瘤分析市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的癌症/腫瘤分析市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 安捷倫與 NCCS 簽署研究合作協議，推動新加坡亞洲常見癌症的基因組分析
    • Sophia Genetics 與安捷倫合作開發癌症分析產品
    • Point32Health 和 Foundation Medicine 擴大了晚期癌症患者全面基因組分析的範圍
    • 協同效應 Laboratories 選擇 SOPHiA GENETICS 技術用於新的癌症分析解決方案
    • Exact Sciences 在美國推出 OncoExTra 癌症治療選擇測試
    • Caris Life Sciences 籌集了 4 億美元，使總資金籌措接近 20 億美元
    • Prenetics 旗下 ACT Genomics 的 ACTOnco 獲得 FDA 批准
    • 安捷倫宣布收​​購用於癌症研究的高性能 NGS靶向序列捕獲工作流程開發商 Avida Biomed
    • Prenetics 收購 ACT Genomics
    • 羅氏首個伴同性診斷獲得 FDA核准，用於識別符合 Enhartu 資格的 HER2 低轉移性乳癌患者
    • CDC 撥款 2.15 億美元推動癌症登月目標

公司名單

  • Takara Bio Inc.
  • Nonacus Limited
  • GenScript Biotech Corporation
  • Tempus Labs Inc.
  • Thermo Fisher Scientific Inc.
  • Hologic, Inc.
  • 4basecare Onco Solutions Private Limited
  • Personalis, Inc.
  • Merck KGaA
  • Exact Sciences Corporation
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings
  • Lucence Health, Inc.
  • Guardant Health, Inc.
  • Sysmex Corporation
  • Agendia, Inc.
  • Paragon Genomics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • HTG Molecular Diagnostics, Inc.
  • NanoString Technologies, Inc.
  • Predictive Oncology Inc.
  • IMBdx, Inc.
  • Perthera, Inc.
  • GENINUS Inc.
  • Genomic Life
  • ACT Genomics Co., Ltd. by Prenetics Global Limited
  • BostonGene Corporation
  • Caris Life Sciences
  • Strand Life Sciences
  • Neogenomics, Inc.
  • Agilent Technologies, Inc.
  • Oncompass Medicine Hungary Kft.
  • OncoDNA SA
Product Code: MRR-374DB5A06C7F

The Cancer/Tumor Profiling Market was valued at USD 10.79 billion in 2023, expected to reach USD 12.77 billion in 2024, and is projected to grow at a CAGR of 18.74%, to USD 35.94 billion by 2030.

Cancer/tumor profiling encompasses a comprehensive analysis of the cancerous cells at a genetic and molecular level, which aids in understanding the complexities of tumor heterogeneity and facilitates personalized treatment strategies. The necessity of cancer profiling arises from its critical role in precision medicine, enabling oncologists to tailor treatments based on individual biomarkers, thus improving therapeutic outcomes and minimizing adverse effects. Its applications span across clinical diagnostics, drug discovery, and oncology research, with end-users comprising hospitals, diagnostic laboratories, research institutes, and pharmaceutical companies. Market growth is primarily driven by the increasing prevalence of cancer, advancements in profiling technologies such as next-generation sequencing (NGS), and heightened demand for personalized medicine. Particularly, the shift towards high-throughput technologies and the development of cost-effective profiling methods present vast opportunities for industry expansion. Additionally, partnerships between pharmaceutical firms and technology developers to enhance targeted therapies could fuel market growth. However, challenges such as high costs associated with advanced sequencing platforms, data privacy concerns, and a dearth of skilled professionals act as significant hindrances. Furthermore, regulatory complexities and reimbursement issues pose additional barriers. Potential areas of innovation lie in the development of integrated bioinformatics solutions and AI-driven analytics to enhance data interpretation and predictive modeling. Expanding R&D efforts in liquid biopsy and non-invasive profiling methods could open new vistas for investors and developers alike. The market is dynamic and evolving, with a trend towards cross-disciplinary collaboration to leverage comprehensive datasets for robust clinical insights. To capitalize on emerging opportunities, stakeholders should focus on enhancing the accessibility and affordability of profiling techniques, building strategic alliances, and investing in workforce training programs to bridge the skill gap. Sustainable growth could be realized by fostering innovations that align with global regulatory standards and meet the diverse needs of the oncology treatment landscape.

KEY MARKET STATISTICS
Base Year [2023] USD 10.79 billion
Estimated Year [2024] USD 12.77 billion
Forecast Year [2030] USD 35.94 billion
CAGR (%) 18.74%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer/Tumor Profiling Market

The Cancer/Tumor Profiling Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing adoption of biomarkers to treat cancer patients
    • Availability of government and global organizations' initiatives for devising cancer diagnosing methods
    • Surging preference for personalized medicines for cancer treatment
  • Market Restraints
    • High capital investment in cancer/tumor profiling instruments and services
  • Market Opportunities
    • Emergence of next-generation sequencing and advancements in tumor profiling
    • Improvements in point-of-care diagnostic technologies to improve cancer detection
  • Market Challenges
    • Low biomarker discovery-to-approval ratio

Porter's Five Forces: A Strategic Tool for Navigating the Cancer/Tumor Profiling Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer/Tumor Profiling Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer/Tumor Profiling Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer/Tumor Profiling Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer/Tumor Profiling Market

A detailed market share analysis in the Cancer/Tumor Profiling Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer/Tumor Profiling Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer/Tumor Profiling Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Cancer/Tumor Profiling Market, highlighting leading vendors and their innovative profiles. These include Takara Bio Inc., Nonacus Limited, GenScript Biotech Corporation, Tempus Labs Inc., Thermo Fisher Scientific Inc., Hologic, Inc., 4basecare Onco Solutions Private Limited, Personalis, Inc., Merck KGaA, Exact Sciences Corporation, Illumina, Inc., Laboratory Corporation of America Holdings, Lucence Health, Inc., Guardant Health, Inc., Sysmex Corporation, Agendia, Inc., Paragon Genomics, Inc., F. Hoffmann-La Roche Ltd., HTG Molecular Diagnostics, Inc., NanoString Technologies, Inc., Predictive Oncology Inc., IMBdx, Inc., Perthera, Inc., GENINUS Inc., Genomic Life, ACT Genomics Co., Ltd. by Prenetics Global Limited, BostonGene Corporation, Caris Life Sciences, Strand Life Sciences, Neogenomics, Inc., Agilent Technologies, Inc., Oncompass Medicine Hungary Kft., and OncoDNA S.A..

Market Segmentation & Coverage

This research report categorizes the Cancer/Tumor Profiling Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Technology, market is studied across Immunoassays, In-Situ Hybridization, Mass Spectrometry, Microarrays, Next-Generation Sequencing, and Polymerase Chain Reaction.
  • Based on Biomarker Type, market is studied across Genomic Biomarker and Protein Biomarker.
  • Based on Cancer Type, market is studied across Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma Cancer, and Prostate Cancer.
  • Based on Application, market is studied across Biomarker Discovery, Clinical Application, Diagnostics, Personalized Medicine, Prognostics, Research, Screening, and Treatment & Monitoring.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing adoption of biomarkers to treat cancer patients
      • 5.1.1.2. Availability of government and global organizations' initiatives for devising cancer diagnosing methods
      • 5.1.1.3. Surging preference for personalized medicines for cancer treatment
    • 5.1.2. Restraints
      • 5.1.2.1. High capital investment in cancer/tumor profiling instruments and services
    • 5.1.3. Opportunities
      • 5.1.3.1. Emergence of next-generation sequencing and advancements in tumor profiling
      • 5.1.3.2. Improvements in point-of-care diagnostic technologies to improve cancer detection
    • 5.1.4. Challenges
      • 5.1.4.1. Low biomarker discovery-to-approval ratio
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technology: Adoption of next-generation sequencing (NGS) for exploring genetic alterations in various cancers
    • 5.2.2. Biomarker Type: Use of genomic biomarkers for the measurement of the expression of a gene, the gene function, and the gene regulation
    • 5.2.3. Cancer Type: Wide preference for cancer profiling in prostate cancers for predictive modeling and clinical risk stratification
    • 5.2.4. Application: Increasing use of cancer/tumor profiling in developing precision medicine to improve healing and recovery time
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cancer/Tumor Profiling Market, by Technology

  • 6.1. Introduction
  • 6.2. Immunoassays
  • 6.3. In-Situ Hybridization
  • 6.4. Mass Spectrometry
  • 6.5. Microarrays
  • 6.6. Next-Generation Sequencing
  • 6.7. Polymerase Chain Reaction

7. Cancer/Tumor Profiling Market, by Biomarker Type

  • 7.1. Introduction
  • 7.2. Genomic Biomarker
  • 7.3. Protein Biomarker

8. Cancer/Tumor Profiling Market, by Cancer Type

  • 8.1. Introduction
  • 8.2. Breast Cancer
  • 8.3. Colorectal Cancer
  • 8.4. Lung Cancer
  • 8.5. Melanoma Cancer
  • 8.6. Prostate Cancer

9. Cancer/Tumor Profiling Market, by Application

  • 9.1. Introduction
  • 9.2. Biomarker Discovery
  • 9.3. Clinical Application
  • 9.4. Diagnostics
  • 9.5. Personalized Medicine
  • 9.6. Prognostics
  • 9.7. Research
  • 9.8. Screening
  • 9.9. Treatment & Monitoring

10. Americas Cancer/Tumor Profiling Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cancer/Tumor Profiling Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cancer/Tumor Profiling Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Agilent and NCCS Sign Research Collaboration Agreement to Advance Singapore's Genomic Profiling on Asian-prevalent Cancers
    • 13.3.2. Sophia Genetics, Agilent Partner on Cancer Analysis Product
    • 13.3.3. Point32Health and Foundation Medicine Expand Access to Comprehensive Genomic Profiling for Members with Advanced Cancer
    • 13.3.4. Synergy Laboratories Taps SOPHiA GENETICS Technology for New Cancer Profiling Solution
    • 13.3.5. Exact Sciences Launches OncoExTra Cancer Therapy Selection Test in the U.S.
    • 13.3.6. Caris Life Sciences nears USD 2B in total funding with USD 400M haul
    • 13.3.7. Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco
    • 13.3.8. Agilent Announces Acquisition of Avida Biomed, Developer of High-Performance NGS Target Enrichment Workflows for Cancer Research
    • 13.3.9. Prenetics Acquires ACT Genomics
    • 13.3.10. Roche receives FDA approval for first companion diagnostic to identify patients with HER2 low metastatic breast cancer eligible for Enhertu
    • 13.3.11. CDC Awards USD 215 Million to Advance Cancer Moonshot Goals

Companies Mentioned

  • 1. Takara Bio Inc.
  • 2. Nonacus Limited
  • 3. GenScript Biotech Corporation
  • 4. Tempus Labs Inc.
  • 5. Thermo Fisher Scientific Inc.
  • 6. Hologic, Inc.
  • 7. 4basecare Onco Solutions Private Limited
  • 8. Personalis, Inc.
  • 9. Merck KGaA
  • 10. Exact Sciences Corporation
  • 11. Illumina, Inc.
  • 12. Laboratory Corporation of America Holdings
  • 13. Lucence Health, Inc.
  • 14. Guardant Health, Inc.
  • 15. Sysmex Corporation
  • 16. Agendia, Inc.
  • 17. Paragon Genomics, Inc.
  • 18. F. Hoffmann-La Roche Ltd.
  • 19. HTG Molecular Diagnostics, Inc.
  • 20. NanoString Technologies, Inc.
  • 21. Predictive Oncology Inc.
  • 22. IMBdx, Inc.
  • 23. Perthera, Inc.
  • 24. GENINUS Inc.
  • 25. Genomic Life
  • 26. ACT Genomics Co., Ltd. by Prenetics Global Limited
  • 27. BostonGene Corporation
  • 28. Caris Life Sciences
  • 29. Strand Life Sciences
  • 30. Neogenomics, Inc.
  • 31. Agilent Technologies, Inc.
  • 32. Oncompass Medicine Hungary Kft.
  • 33. OncoDNA S.A.

LIST OF FIGURES

  • FIGURE 1. CANCER/TUMOR PROFILING MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER/TUMOR PROFILING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CANCER/TUMOR PROFILING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CANCER/TUMOR PROFILING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CANCER/TUMOR PROFILING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CANCER/TUMOR PROFILING MARKET DYNAMICS
  • TABLE 7. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IN-SITU HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GENOMIC BIOMARKER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROTEIN BIOMARKER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MELANOMA CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL APPLICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TREATMENT & MONITORING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 72. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 76. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 80. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 84. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 88. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 92. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 96. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 100. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 104. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 108. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 116. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 117. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 121. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 125. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 129. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 133. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 137. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 141. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 145. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 149. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 153. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 157. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 161. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 165. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 169. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. SOUTH AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 173. SOUTH AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SOUTH AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SOUTH AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. SPAIN CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 177. SPAIN CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SPAIN CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. SPAIN CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. SWEDEN CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 181. SWEDEN CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. SWEDEN CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. SWEDEN CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 184. SWITZERLAND CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 185. SWITZERLAND CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. SWITZERLAND CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. SWITZERLAND CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. TURKEY CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 189. TURKEY CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. TURKEY CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. TURKEY CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED ARAB EMIRATES CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED ARAB EMIRATES CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED ARAB EMIRATES CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED ARAB EMIRATES CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 196. UNITED KINGDOM CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 197. UNITED KINGDOM CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. UNITED KINGDOM CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. UNITED KINGDOM CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 200. CANCER/TUMOR PROFILING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 201. CANCER/TUMOR PROFILING MARKET, FPNV POSITIONING MATRIX, 2023